Concurrent CDK7 and CDK9 Blockade Sustains Transcriptional Shutdown and Suppresses Oncogenic Dependencies in Cancer

Transcriptional cyclin-dependent kinases (CDKs) are attractive cancer targets owned to their critical role in the regulation of RNA polymerase II (RNAPII) to maintain oncogenic gene-expression programs. CDK7 supports transcriptional initiation and promoter escape, whereas CDK9 promotes productive elongation. Because inhibition of a single node can be partially buffered by transcriptional plasticity, we tested whether co-targeting CDK7 and CDK9 enforces a deeper and more durable transcriptional shutdown with improved antitumor activity. By combining genetic and pharmacological perturbations across breast and ovarian cancer models, we found that dual CDK7–CDK9 knockout caused the strongest suppression of proliferation and nascent RNA synthesis, accompanied by greater loss of RNAPII phosphorylation and pronounced depletion of MYC and MCL1, compared with single knockouts. Pharmacological co-inhibition phenocopied these effects, producing rapid EU suppression that preceded decreases in EdU incorporation and cell number, preventing adaptation to single treatments and yielding deeper pathway inhibition than either monotherapy. In ovarian cancer models, combined inhibition similarly enhanced suppression of transcriptional output and growth relative to single agents, supporting generalizability across tumor contexts. RNA sequencing after short inhibitor exposures showed that combined CDK7/CDK9 inhibition induced a transcriptomic state distinct from either single agent, with broad downregulation of pathways linked to transcription and RNA processing, ribosome biogenesis, and growth-associated programs. Together, these data support CDK7/CDK9 co-targeting as a mechanistically grounded strategy to intensify and stabilize transcriptional inhibition in cancer, coupling proximal RNAPII control to depletion of short-lived oncogenic drivers and collapse of growth-promoting networks and providing a clear rationale for combinatorial therapeutic development.